WHO Drug Information Vol. 15, No. 3 & 4, 2001
(2001; 76 pages) View the PDF document
Table of Contents
View the documentWHO Drug Information
Open this folder and view contentsPersonal Perspectives
Open this folder and view contentsReports on Individual Drugs
Open this folder and view contentsQuality Assurance Issues
Open this folder and view contentsCurrent Topics
Open this folder and view contentsGeneral Information
Close this folderRegulatory and Safety Matters*
View the documentInfliximab and congestive heart failure
View the documentInfliximab: warning of opportunistic infections
View the documentBrimonidine ophthalmic drops: accidental ingestion
View the documentP-Glycoprotein and drug interaction
View the documentNonacog alfa: intensive surveillance
View the documentTenofovir disoproxil fumarate approved for HIV infection
View the documentCiprofloxacin hydrochloride for inhalation anthrax
View the documentDTPa and limb swelling
View the documentNitrofurantoin and peripheral neuropathy
View the documentContinued suspension for tolcapone
View the documentMMR vaccine and idiopathic thrombocytopenic purpura
View the documentNew communications and networking unit at EMEA
Open this folder and view contentsATC/DDD Classification
Open this folder and view contentsRegulatory Information
View the documentRecommended International Nonproprietary Names (rec. Inn): List 46
View the documentSelected WHO Publications of Related Interest
 

MMR vaccine and idiopathic thrombocytopenic purpura

United Kingdom - Thrombocytopenia is a well-recognized rare adverse reaction with measles, mumps, rubella (MMR) vaccine which is listed in the product information.

A recently published study conducted by the Public Health Laboratory Service has found the absolute risk of a child developing idiopathic thrombocytopenic purpura (ITP) within 6 weeks of the first dose of MMR to be 1 in 22,300 cases with 2 out of every 3 cases being attributable to MMR (1).

The Committee for Safety of Medicines has recommended:

• Children who developed ITP within 6 weeks of the first dose of MMR (or its component vaccines should have their serological status evaluated before the second dose is due. If serology testing suggests that a child is not fully immune against measles, mumps and rubella then a second dose of MMR is recommended.

• The Public Health Laboratory Service are offering a free serological testing service for children developing ITP within 6 weeks of the first dose of MMR.

Reference: Current Problems in Pharmacovigilance, Volume 27, August 2001.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 29, 2018